



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/045,970	01/11/2002	Rami Lidor-Hadas	1662/55602	3018

26646 7590 05/20/2005

KENYON & KENYON
ONE BROADWAY
NEW YORK, NY 10004

EXAMINER

STOCKTON, LAURA

ART UNIT	PAPER NUMBER
----------	--------------

1626

DATE MAILED: 05/20/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/045,970

Applicant(s)

LIDOR-HADAS ET AL.

Examiner

Laura L. Stockton, Ph.D.

Art Unit

1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on February 17, 2005 & February 25, 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-3 and 42-50 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3 and 42-50 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 2/17/05.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

Claims 1-3 and 42-50 are pending in the application.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114 was filed in this application after appeal to the Board of Patent Appeals and Interferences, but prior to a decision on the appeal. Since this application is eligible for continued examination under 37 CFR 1.114 and the fee set forth in 37 CFR 1.17(e) has been timely paid, the appeal has been withdrawn pursuant to 37 CFR 1.114 and prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on February 17, 2005 has been entered.

Election/Restrictions

Applicants' election without traverse of Group I in Paper No. 7 was acknowledged in a previous Office

Art Unit: 1626

Action. The requirement was deemed proper and made FINAL in a previous Office Action.

Information Disclosure Statement

The Information Disclosure Statement(s) filed on February 17, 2005 has been considered by the Examiner.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3 and 42-50 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the

Art Unit: 1626

specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

No persuasive support could be found in the specification or the originally filed claims for "an exo-methylene content of less than about 0.1%" as found in claims 1-3 and 42-47. Applicants state that support is found on page 2, lines 15-16 and Example 4. However, page 2, lines 15-16 identifies the exo-methylene as a by-product and Example 4 does not indicate a exo-methylene content of less than about 0.1%. Therefore, the claims lack written description as such.

Response to Amendment

The Declaration under 37 CFR 1.132 filed February 17, 2005 is insufficient to overcome the rejection of claims 1-3 and 42-47 based upon

Art Unit: 1626

obviousness under 35 USC § 103 over Chen {Zhongguo Yiyao Gongye Zazhi (1993), 24(6), pages 241-242}, Tyers {U.S. Pat. 4,845,115}, Coates et al. {U.S. Pat. 4,695,578} and Tyers {U.S. Pat. 4,835,173} as set forth in the last Office action because: (1) the Declaration states, not shows, that the prior art does not have a purity of at least about 99.0%, see paragraph 2 on page 1; (2) the Declaration states that the product produced in Coates et al. has 0.12% of the exo-methylene whereas Applicants' claim that their product has less than about 0.1% of the exo-methylene, which reads of Coates et al.'s 0.12%, see paragraph 3 of Declaration and instant claim 1, for example; (3) the Declaration fails to show that the instant claimed product has a viable unexpected, unobvious and superior property, not just of allegedly higher purity; and (4) the Declaration is unclear if the cited prior art were compared with the instant claimed invention, see Table 3, for example.

Art Unit: 1626

Further, claims 42-50 are product-by-process claims. "Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985). Also see M.P.E.P. 2113.

Since no other ingredient than the Ondansetron hydrochloride dihydrate is present in the pharmaceutical formulation, claims 45-47 and 50 are interpreted as compound claims.

Art Unit: 1626

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-3 and 42-50 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chen {Zhongguo Yiyao Gongye Zazhi (1993), 24(6), pages 241-242}, Tyers {U.S. Pat. 4,845,115}, Coates et al. {U.S. Pat. 4,695,578}, Tyers {U.S. Pat. 4,835,173} and Lidor-Hadas et al. {WO 02/36558}, each taken alone or in combination with each other when similar utilities are asserted. An English translation of Chen was previously provided and will be referred to hereinafter.

Art Unit: 1626

Determination of the scope and content of the prior art

(MPEP §2141.01)

Applicants claim Ondansetron hydrochloride dihydrate. Each of Chen {page 1, Compound (1) and page 2- section III}, Tyers '115 {column 3 and especially Example 2 in column 3}, Coates et al. {column 4 and especially Example 10 in column 20} and Tyers '173 {column 3 and especially Example 2 in column 3} and Lidor-Hadas et al. {page 3, lines 12-21 - Form A} teach Ondansetron hydrochloride dihydrate.

Ascertainment of the difference between the prior art

and the claims (MPEP §2141.02)

The difference between the instant claimed invention and the prior art is that the prior art is silent as to the purity of the product obtained.

Art Unit: 1626

***Finding of prima facie obviousness--rational and
motivation (MPEP §2142-2413)***

Changing the form, purity, color, or other characteristic of an old product without a new use as a result thereof does not render product patentable where utility remains the same. Ex parte Hartop, 139 USPQ 525. The compounds are of the same identical formula and as such would be expected to have the same utility. The difference, if any, may reside in there being of a higher purity.

One of ordinary skill in the art would be motivated to prepare a purer form of a known organic pharmaceutically active compound in the expectation of obtaining that very compound but with enhanced properties, e.g. improved solubility, shelf-life, improved mode of administering properties, etc. In the absence of a showing of a viable unexpected, unobvious and superior property (not just an alleged higher

purity), the instant claimed invention is found obvious over the cited prior art.

Response to Arguments

Applicants' arguments filed February 17, 2005 and February 25, 2005 have been fully considered. Applicants argue that: (1) none of the references cited explicitly or implicitly disclose Ondansetron hydrochloride dihydrate with an exo-methylene content of less than about 0.1%; (2) all of the references disclose the same inferior process that results in much greater quantities of the exo-methylene impurity; (3) Coates et al. purification process gives Ondansetron hydrochloride dihydrate containing 0.12% exo-methylene whereas the present invention has only 0.01% or an undetectable amount of exo-methylene; (4) all of the prior art use the solvent system of isopropanol and water whereas Applicants' use a solvent system of water alone and utilizing activated carbon; and (5) the

Art Unit: 1626

amounts of starting material used in the prior art are different versus the amounts of the starting material used in preparing the claimed product.

All of Applicants' arguments have been considered but have not been found persuasive. Applicants argue that none of the references cited explicitly or implicitly disclose Ondansetron hydrochloride dihydrate with an exo-methylene content of less than about 0.1% and that all of the references disclose the same inferior process that results in much greater quantities of the exo-methylene impurity. In response, according to the Declaration filed on February 17, 2005 by Dr. Ramy Lidor-Hadas, the Declaration states that the product produced in Coates et al. has 0.12% of the exo-methylene whereas Applicants' claim that their product has less than about 0.1% of the exo-methylene, which reads of Coates et al.'s 0.12%, see paragraph 3 of Declaration and instant claim 1, for example.

Applicants' argue that Coates et al.'s purification process gives Ondansetron hydrochloride dihydrate containing 0.12% exo-methylene whereas the present invention has only 0.01% or an undetectable amount of exo-methylene. In response, Applicants are arguing limitations not found in the instant claims. Claim 1, for example, states "an exo-methylene content of less than about 0.1%." not 0.01%.

Applicants argue that all of the prior art use the solvent system of isopropanol and water whereas Applicants' use a solvent system of water alone and utilize activated carbon and the amounts of starting material used in the prior art is different versus the amounts of the starting material used in preparing the claimed product. In response, Claims 1-3 and 42-50 are directed to compounds not processes of making. Further, claims 42-50 are product-by-process claims. "Even though product-by-process claims are limited by and defined by the process, determination of

Art Unit: 1626

patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985). Also see M.P.E.P. 2113.

The compounds are of the same identical formula and as such would be expected to have the same utility. The difference, if any, may reside in there being of a higher purity. One of ordinary skill in the art would be motivated to prepare a purer form of a known organic pharmaceutically active compound in the expectation of obtaining that very compound but with enhanced properties, e.g. improved solubility, shelf-life, improved mode of administering properties, etc. In the absence of a showing of a viable unexpected, unobvious and superior property (not just an alleged higher


Art Unit: 1626

purity), the instant claimed invention is found obvious over the cited prior art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura L. Stockton whose telephone number is (571) 272-0710. The examiner can normally be reached on Monday-Friday from 6:15 am to 2:45 pm. If the examiner is out of the Office, the examiner's supervisor, Joseph McKane, can be reached on (571) 272-0699.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

The Official fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

A handwritten signature in black ink, appearing to read "Laura L. Stockton", written over a horizontal line.

Laura L. Stockton, Ph.D.

Patent Examiner

Art Unit 1626, Group 1620

Technology Center 1600

May 16, 2005